Clinical Trials Browser

Interventional × HM781-36B × Clear all

NCT03066206 2026-02-20

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT05378763 2026-02-18

PINNACLE

Phase 3 Suspended

NSCLC

NCT03318939 2024-04-03

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Phase 2 Terminated

NSCLC

NCT03744715 2024-03-05

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Phase 2 Terminated

Breast Neoplasms

NCT05045404 2023-09-13

Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03292250 2022-03-29

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02659514 2022-03-11

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

Phase 2 Completed

67 enrolled 16 charts

Breast Neoplasms

NCT02418689 2022-01-20

Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens

Phase 2 Completed

Breast Neoplasms

NCT03429101 2021-01-15

A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT04044170 2020-11-17

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Phase 2 Terminated

NSCLC

NCT02544997 2020-07-07

A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway

Phase 2 Completed

Breast Neoplasms

NCT02216916 2019-03-18

Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT03770988 2019-02-22

A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)

Phase 2 Unknown

Recurrence

NCT02979821 2018-05-24

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

Phase 2 Completed

Adenocarcinoma of Lung

NCT01746771 2016-03-03

A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

Phase 1/2 Completed

Gastrointestinal

HER-2 Positive Advanced Gastric Cancer

NCT01819428 2016-03-01

NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma

Phase 2 Terminated

Adenocarcinoma of Lung

NCT01455571 2014-02-26

Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT01455584 2013-05-23

Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors

Phase 1 Completed

Advanced Solid Malignancies